The registration of the finished dosage form (FDF) of nadroparin calcium, a modern low-molecular-weight heparin, has been successfully completed in Russia. This was reported by the Press Service of the Siberian State Medical University (SSMU). The launch of the drug on the market is the result of a strategic partnership between the university, Pharmbioprom company, and SPbSRIVS of the FMBA of Russia.
From Laboratory to Production
The project was implemented with the financial support of the Ministry of Education and Science of the Russian Federation. Obtaining registration confirms that the Russian development has passed the full cycle: from scientific research in a university laboratory to the transfer of technology to a real production site.
The drug is intended for wide use in cardiological, surgical, and therapeutic practice, where low-molecular-weight heparins are the “gold standard” of anticoagulant therapy.
“Drug registration is a practical result of our work on transferring science to industry. We are consistently implementing a strategy aimed at translating research and development results into real market technologies, and this project is its vivid embodiment.”
— Olga Fedorova, Vice-Rector for Research and Postgraduate Training, SSMU
Course for Full Cycle
The creation of the drug was made possible thanks to the scientific and technological infrastructure of the university, developed under the “Priority 2030” program. At this stage, the finished dosage form is registered, but the partners aim to deepen localization.
Plans include completing the registration of their own Russian pharmaceutical substance of nadroparin calcium by the end of 2026. The introduction of full-cycle production technology will make a significant contribution to ensuring Russia’s drug security in the segment of vital anticoagulants.
